BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//TrialSonar//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:TrialSonar · $2696.HK readouts
X-WR-CALDESC:Clinical-trial primary completion dates from ClinicalTrials.go
 v\, refreshed nightly by TrialSonar. Not investment advice.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06839066-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20261122
DTEND;VALUE=DATE:20261123
SUMMARY:HLX43 DOSE 1 readout (P2) · Shanghai Henlius Biotech $2696.HK
DESCRIPTION:A Phase II Study to Evaluate HLX43 in Subjects With Recurrent/M
 etastatic Nasopharyngeal Carcinoma Failed or Intolerance to Second-line Th
 erapy\n\nPrimary completion date: 2026-11-22 (estimated)\nPhase 2 · Oncol
 ogy · Nasopharyngeal Carcinoma (NPC)\nEnrollment: 70 · Sites: 15\n\nPrim
 ary completion = last participant's primary-endpoint data collected\; topl
 ine results usually follow weeks to months later. Sponsor-reported\, often
  an estimate. Not investment advice.\n\nhttps://datacutoff.com/rad
 ar.html?nct=NCT06839066\nhttps://clinicaltrials.gov/study/NCT06839066
URL:https://datacutoff.com/radar.html?nct=NCT06839066
CATEGORIES:Oncology,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07106892-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:HLX43 Dose 1\; readout (P2) · Shanghai Henlius Biotech $2696.HK
DESCRIPTION:Phase II\, Open-label\, Multicenter Study to Evaluate the Effic
 acy and Safety of HLX43 (an Anti-PD-L1 ADC) in Subjects With Advanced Colo
 rectal Cancer\n\nPrimary completion date: 2026-12-30 (estimated)\nPhase 2 
 · Oncology · Colorectal Cancer (CRC)\nEnrollment: 60 · Sites: 2\n\nPrim
 ary completion = last participant's primary-endpoint data collected\; topl
 ine results usually follow weeks to months later. Sponsor-reported\, often
  an estimate. Not investment advice.\n\nhttps://datacutoff.com/rad
 ar.html?nct=NCT07106892\nhttps://clinicaltrials.gov/study/NCT07106892
URL:https://datacutoff.com/radar.html?nct=NCT07106892
CATEGORIES:Oncology,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07459738-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:HLX43 readout (P2) · Shanghai Henlius Biotech $2696.HK
DESCRIPTION:A Phase II Study to Evaluate the Efficacy and Safety of HLX43 i
 n Patients With Hormone Receptor Positive\, HER2 Negative Locally Advanced
  or Metastatic Breast Cancer\n\nPrimary completion date: 2026-12-30 (estim
 ated)\nPhase 2 · Oncology · Hormone Receptor Positive HER-2 Negative Bre
 ast Cancer\nEnrollment: 60 · Sites: 0\n\nPrimary completion = last partic
 ipant's primary-endpoint data collected\; topline results usually follow w
 eeks to months later. Sponsor-reported\, often an estimate. Not investment
  advice.\n\nhttps://datacutoff.com/radar.html?nct=NCT07459738\nhtt
 ps://clinicaltrials.gov/study/NCT07459738
URL:https://datacutoff.com/radar.html?nct=NCT07459738
CATEGORIES:Oncology,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06769152-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:HLX43 readout (P2) · Shanghai Henlius Biotech $2696.HK
DESCRIPTION:A Phase II Clinical Study to Evaluate the Efficacy and Safety o
 f HLX43 (Anti-PD-L1 ADC) in Patients With Advanced Gynecological Malignant
  Tumors\n\nPrimary completion date: 2026-12-31 (estimated)\nOriginally pla
 nned: 2026-10-31 (+2.0 months)\nPhase 2 · Oncology · Cervical Cancer\, O
 varian Cancer\nEnrollment: 190 · Sites: 1\n\nPrimary completion = last pa
 rticipant's primary-endpoint data collected\; topline results usually foll
 ow weeks to months later. Sponsor-reported\, often an estimate. Not invest
 ment advice.\n\nhttps://datacutoff.com/radar.html?nct=NCT06769152\
 nhttps://clinicaltrials.gov/study/NCT06769152
URL:https://datacutoff.com/radar.html?nct=NCT06769152
CATEGORIES:Oncology,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07038382-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:~HLX79 10mg/kg/Placebo+HLX01 readout (P2) · Shanghai Henlius Biote
 ch $2696.HK
DESCRIPTION:A Study to Evaluate the Efficacy\, Safety\, and Tolerability of
  Human Sialidase Fusion Protein (HLX79) in Combination With Rituximab Inje
 ction Versus Placebo in Patients With Active…\n\nPrimary completion date
 : 2027-01 (estimated) — month only\, shown on the 1st\nPhase 2 · Immuno
  · Membranous Nephropathy\, Lupus Nephritis (LN)\nEnrollment: 24 · Sites
 : 17\n\nPrimary completion = last participant's primary-endpoint data coll
 ected\; topline results usually follow weeks to months later. Sponsor-repo
 rted\, often an estimate. Not investment advice.\n\nhttps://trialsonar.net
 lify.app/radar.html?nct=NCT07038382\nhttps://clinicaltrials.gov/study/NCT0
 7038382
URL:https://datacutoff.com/radar.html?nct=NCT07038382
CATEGORIES:Immuno,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06349980-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270210
DTEND;VALUE=DATE:20270211
SUMMARY:HLX53 (1000mg) readout (P2) · Shanghai Henlius Biotech $2696.HK
DESCRIPTION:A Study to Explore the Reasonable Dosage and Evaluate the Effic
 acy\, Safety and Tolerability of HLX10 and HLX04 with or Without HLX53 in 
 Untreated\, Locally Advanced or Metastatic H…\n\nPrimary completion date
 : 2027-02-10 (estimated)\nPhase 2 · Oncology · Carcinoma\, Hepatocellula
 r\nEnrollment: 117 · Sites: 1\n\nPrimary completion = last participant's 
 primary-endpoint data collected\; topline results usually follow weeks to 
 months later. Sponsor-reported\, often an estimate. Not investment advice.
 \n\nhttps://datacutoff.com/radar.html?nct=NCT06349980\nhttps://cli
 nicaltrials.gov/study/NCT06349980
URL:https://datacutoff.com/radar.html?nct=NCT06349980
CATEGORIES:Oncology,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06847334-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270409
DTEND;VALUE=DATE:20270410
SUMMARY:HLX17 readout (P3) · Shanghai Henlius Biotech $2696.HK
DESCRIPTION:A Study to Compare the Efficacy\, Safety\, Immunogenicity\, and
  Pharmacokinetic Profile of HLX17 Vs. Keytruda® in the First-Line Treatme
 nt of Advanced Non-squamous Non-small Cell Lun…\n\nPrimary completion da
 te: 2027-04-09 (estimated)\nPhase 3 · Oncology · Non-Squamous Non-Small 
 Cell Lung Cancer\nEnrollment: 772 · Sites: 0\n\nPrimary completion = last
  participant's primary-endpoint data collected\; topline results usually f
 ollow weeks to months later. Sponsor-reported\, often an estimate. Not inv
 estment advice.\n\nhttps://datacutoff.com/radar.html?nct=NCT068473
 34\nhttps://clinicaltrials.gov/study/NCT06847334
URL:https://datacutoff.com/radar.html?nct=NCT06847334
CATEGORIES:Oncology,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07487519-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270515
DTEND;VALUE=DATE:20270516
SUMMARY:HLX43 DOSE 1 IN ≥2L TNBC readout (P2) · Shanghai Henlius Biotech
  $2696.HK
DESCRIPTION:Phase II Study of HLX43 Monotherapy or Combined With Immune Che
 ckpoint Inhibitors in Patients With Locally Advanced\, Recurrent\, or Meta
 static Triple-negative Breast Cancer.\n\nPrimary completion date: 2027-05-
 15 (estimated)\nPhase 2 · Oncology · Breast Cancer (Triple Negative Brea
 st Cancer (TNBC))\nEnrollment: 180 · Sites: 1\n\nPrimary completion = las
 t participant's primary-endpoint data collected\; topline results usually 
 follow weeks to months later. Sponsor-reported\, often an estimate. Not in
 vestment advice.\n\nhttps://datacutoff.com/radar.html?nct=NCT07487
 519\nhttps://clinicaltrials.gov/study/NCT07487519
URL:https://datacutoff.com/radar.html?nct=NCT07487519
CATEGORIES:Oncology,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06532006-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270601
DTEND;VALUE=DATE:20270602
SUMMARY:HLX22 readout (P3) · Shanghai Henlius Biotech $2696.HK
DESCRIPTION:A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuz
 umab and Chemotherapy for the Treatment of Gastroesophageal Junction and G
 astric Cancer\n\nPrimary completion date: 2027-06-01 (estimated)\nPhase 3 
 · Oncology · Gastroesophageal-junction Cancer\, Monoclonal Antibody\, Ga
 stric Cancer\nEnrollment: 550 · Sites: 208\n\nPrimary completion = last p
 articipant's primary-endpoint data collected\; topline results usually fol
 low weeks to months later. Sponsor-reported\, often an estimate. Not inves
 tment advice.\n\nhttps://datacutoff.com/radar.html?nct=NCT06532006
 \nhttps://clinicaltrials.gov/study/NCT06532006
URL:https://datacutoff.com/radar.html?nct=NCT06532006
CATEGORIES:Oncology,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06832202-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270601
DTEND;VALUE=DATE:20270602
SUMMARY:HLX22 readout (P2) · Shanghai Henlius Biotech $2696.HK
DESCRIPTION:A Phase II Study of HLX22 in Combination With Trastuzumab Derux
 tecan in HER2-low\, Hormone Receptor Positive Locally Advanced or Metastat
 ic Breast Cancer Patients\n\nPrimary completion date: 2027-06-01 (estimate
 d)\nPhase 2 · Oncology · HER2-low Hormone Receptor Positive Breast Cance
 r\nEnrollment: 50 · Sites: 1\n\nPrimary completion = last participant's p
 rimary-endpoint data collected\; topline results usually follow weeks to m
 onths later. Sponsor-reported\, often an estimate. Not investment advice.\
 n\nhttps://datacutoff.com/radar.html?nct=NCT06832202\nhttps://clin
 icaltrials.gov/study/NCT06832202
URL:https://datacutoff.com/radar.html?nct=NCT06832202
CATEGORIES:Oncology,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06841185-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270606
DTEND;VALUE=DATE:20270607
SUMMARY:HLX13 readout (P3) · Shanghai Henlius Biotech $2696.HK
DESCRIPTION:A Study to Compare the Efficacy\, Safety\, Immunogenicity\, and
  Pharmacokinetic Profile of HLX13 with YERVOY As a First-Line Treatment fo
 r Patients with Unresectable Hepatocellular C…\n\nPrimary completion dat
 e: 2027-06-06 (estimated)\nPhase 3 · Oncology · Hepatocellular Carcinoma
  (HCC)\nEnrollment: 656 · Sites: 0\n\nPrimary completion = last participa
 nt's primary-endpoint data collected\; topline results usually follow week
 s to months later. Sponsor-reported\, often an estimate. Not investment ad
 vice.\n\nhttps://datacutoff.com/radar.html?nct=NCT06841185\nhttps:
 //clinicaltrials.gov/study/NCT06841185
URL:https://datacutoff.com/radar.html?nct=NCT06841185
CATEGORIES:Oncology,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07253142-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270618
DTEND;VALUE=DATE:20270619
SUMMARY:HLX43 dose 1 readout (P2) · Shanghai Henlius Biotech $2696.HK
DESCRIPTION:A Phase II Clinical Study to Evaluate HLX43 in Combination With
  Serplulimab in Subjects With Advanced Lung Cancer\n\nPrimary completion d
 ate: 2027-06-18 (estimated)\nPhase 2 · Oncology · Non Small Cell Lung Ca
 ncer\, Small Cell Lung Cancer\nEnrollment: 120 · Sites: 10\n\nPrimary com
 pletion = last participant's primary-endpoint data collected\; topline res
 ults usually follow weeks to months later. Sponsor-reported\, often an est
 imate. Not investment advice.\n\nhttps://datacutoff.com/radar.html
 ?nct=NCT07253142\nhttps://clinicaltrials.gov/study/NCT07253142
URL:https://datacutoff.com/radar.html?nct=NCT07253142
CATEGORIES:Oncology,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06895512-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270701
DTEND;VALUE=DATE:20270702
SUMMARY:~HLX15-IV readout (P3) · Shanghai Henlius Biotech $2696.HK
DESCRIPTION:A Study to Evaluate the Efficacy and Safety of HLX15-IV Versus 
 DARZALEX® in Combination with Lenalidomide-Dexamethasone (Rd) in Transpla
 nt-ineligible Patients with Newly Diagnosed…\n\nPrimary completion date:
  2027-07 (estimated) — month only\, shown on the 1st\nPhase 3 · Oncolog
 y · Newly Diagnosed Multiple Myeloma\nEnrollment: 386 · Sites: 1\n\nPrim
 ary completion = last participant's primary-endpoint data collected\; topl
 ine results usually follow weeks to months later. Sponsor-reported\, often
  an estimate. Not investment advice.\n\nhttps://datacutoff.com/rad
 ar.html?nct=NCT06895512\nhttps://clinicaltrials.gov/study/NCT06895512
URL:https://datacutoff.com/radar.html?nct=NCT06895512
CATEGORIES:Oncology,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07115485-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270830
DTEND;VALUE=DATE:20270831
SUMMARY:HLX43 DOSE 1 readout (P2) · Shanghai Henlius Biotech $2696.HK
DESCRIPTION:Phase II\, Open-label\, Multicenter Study to Evaluate the Effic
 acy and Safety of HLX43 (an Anti-PD-L1 ADC) in Subjects With Advanced Gast
 ric or Gastroesophageal Junction Adenocarcin…\n\nPrimary completion date
 : 2027-08-30 (estimated)\nPhase 2 · Oncology · Gastric or Gastroesophage
 al Junction Adenocarcinoma\nEnrollment: 60 · Sites: 1\n\nPrimary completi
 on = last participant's primary-endpoint data collected\; topline results 
 usually follow weeks to months later. Sponsor-reported\, often an estimate
 . Not investment advice.\n\nhttps://datacutoff.com/radar.html?nct=
 NCT07115485\nhttps://clinicaltrials.gov/study/NCT07115485
URL:https://datacutoff.com/radar.html?nct=NCT07115485
CATEGORIES:Oncology,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
